Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A third look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Ticker(s): 1801.XHKG

Who's the expert?

Institution: LakeView Healthcare System

Cardiologist who sees over 100 patients on anticoagulation medications
Medical School: M.D Albert Einstein College of Medicine. Residency: Hospital of the Albert Einstein College of Medicine Fellowship: Albert Einstein College of Medicine
Research interest in cardiac problems during pregnancy

Interview Goal

To discuss the current standard of care and the potential of Sintbilo (Tafolecimab Injection), an anti-PCSK9 monoclonal antibody being developed by Innovent Biologics for the treatment of patients with primary hypercholesterolemia and mixed dyslipidemia.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.